Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab Neoadjuvant Therapy in MSI-H/dMMR Stage II–III Colorectal Cancer
CTR20212779Phase 2Completed
- Sponsor
- BeiGene
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in colorectal cancer (CRC), sponsored by BeiGene. Started Nov 2021; status: completed.
02
Drugs
tislelizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20212779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212779.